Patents by Inventor Richard T. Layer
Richard T. Layer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20170151286Abstract: Injectable mediums and methods for preparing and administering an injectable medium comprising therapeutic cells, and optionally one or more therapeutic or diagnostic substance, suitable for injection into an anatomical space of a human or animal subject, comprising hyaluronic acid in concentrations of 0.5 weight percent to 1.0 weight percent having a molecular weight of about ?700 kDa to about 1,900 kDa and a storage modulus within the range of 5-25 Pa, which injectable mediums and methods prevent cell settling during transportation and storage of such injectable mediums comprising therapeutic cells, and optionally therapeutic or diagnostic substances; promote cell survival; facilitate administration of homogeneous injectable mediums comprising therapeutic cells, in particular NSCs; and enable rapid clearance by the body following injection, so as not to interfere with cellular integration with surrounding tissue.Type: ApplicationFiled: November 28, 2016Publication date: June 1, 2017Inventors: Artem B. Kutikov, Richard T. Layer, Simon W. Moore, Thomas R. Ulich, Alex A. Aimetti
-
Publication number: 20170151416Abstract: Injection devices and methods for delivering a trail of therapeutic cells and/or one or more therapeutic substances or diagnostic substances or injectable medium into an anatomical space of an animal or human subject, particularly a trail of therapeutic cells and/or one or more therapeutic substances or diagnostic substances or injectable medium into the spinal cord of a subject and to deliver a trail of therapeutic cells and/or one or more therapeutic substances or diagnostic substances or injectable medium inside the spinal cord, to treat an injury or disorder of the central nervous system requiring injection of cells and/or one more therapeutic substances. The devices and methods are useful for the treatment of a variety of traumas, conditions and diseases, in particular, spinal cord injuries, amyotrophic lateral sclerosis, multiple sclerosis and spinal ischemia as well as other spinal cord degenerative conditions and pathologies.Type: ApplicationFiled: November 28, 2016Publication date: June 1, 2017Inventors: Artem B. Kutikov, Richard T. Layer, Simon W. Moore, Thomas R. Ulich, James D. Guest, Alex A. Aimetti, Robert Charles, Brendan P. Collins, Jon Taylor, Eugene Zeleny
-
Patent number: 6855805Abstract: The invention relates to relatively short peptides (termed ?-conotoxins herein), about 10-25 residues in length, which are naturally available in minute amounts in the venom of the cone snails or analogous to the naturally available peptides, and which preferably include two disulfide bonds. The ?-conotoxins, as described herein, are useful for as neuromuscular blocking agents, such as muscle relaxants.Type: GrantFiled: July 20, 2001Date of Patent: February 15, 2005Assignees: University of Utah Research Foundation, Cognetix, Inc.Inventors: Baldomero M. Olivera, Richard T. Layer, J. Michael McIntosh, Jacob Scott Nielsen, Robert M. Jones
-
Publication number: 20040259794Abstract: The present invention is directed to the new &mgr;O-conopeptides, their coding sequences and their propeptides and to the use of &mgr;O-conopeptides as a local anesthetic for treating pain. The &mgr;O-conopeptides have long lasting anesthetic activity and are particularly useful for spinal anesthesia, either administered acutely for post-operative pain or via an intrathecal pump for severe chronic pain situations or for treatment of pain in epithelial tissue.Type: ApplicationFiled: July 9, 2004Publication date: December 23, 2004Applicants: Cognetix, Inc., University of Utah Research FoundationInventors: Baldomero M. Olivera, J. Michael McIntosh, R. Tyler McCabe, James E. Garrett, Richard T. Layer, John D. Wagstaff, Robert M. Jones
-
Publication number: 20040204362Abstract: The invention relates to relatively short peptides (termed &agr;-conotoxins herein), about 10-25 residues in length, which are naturally available in minute amounts in the venom of the cone snails or analogous to the naturally available peptides, and which preferably include two disulfide bonds. The &agr;-conotoxins, as described herein, are useful for as neuromuscular blocking agents, such as muscle relaxants.Type: ApplicationFiled: May 6, 2004Publication date: October 14, 2004Applicants: The University of Utah Research Foundation, Cognetix, Inc.Inventors: Baldomero M. Olivera, Richard T. Layer, Maren Watkins, David R. Hillyard, J. Michael McIntosh, Robert Schoenfeld, Jacob Scott Nielsen, Robert M. Jones
-
Patent number: 6762165Abstract: The invention relates to relatively short peptides (termed O-Superfamily conotoxins herein), about 20-40 residues in length, which are naturally available in minute amounts in the venom of the cone snails or analogous to the naturally available peptides, and which preferably include two disulfide bonds.Type: GrantFiled: December 28, 2000Date of Patent: July 13, 2004Assignees: University of Utah Research Foundation, Cognetix, Inc.Inventors: Baldomero M. Olivera, G. Edward Cartier, Maren Watkins, David R. Hillyard, J. Michael McIntosh, Richard T. Layer, Robert M. Jones
-
Publication number: 20040092447Abstract: The invention relates to uses of kappa-conotoxin PVIIA (&kgr;-PVIIA), analogs and derivatives for activating ATP-sensitive K+ channels. The activation of ATP-sensitive K+ channels is useful for opening KATP channels which can be used to treat a wide range of disease and injury states, including cerebral and cardiac ischemia and asthma.Type: ApplicationFiled: July 28, 2003Publication date: May 13, 2004Applicant: Cognetix, Inc.Inventors: Ann H. Cornell-Bell, Karen E. Pemberton, Davis L. Temple, Richard T. Layer, R. Tyler McCabe, Robert M. Jones
-
Publication number: 20040072758Abstract: The present invention is directed to contulakin-G (which is the native glycosylated peptide), a des-glycosylated contulakin-G (termed Thr10-contulakin-G), and derivatives thereof, to a cDNA clone encoding a precursor of this mature peptide and to a precursor peptide. The invention is further directed to the use of this peptide as a therapeutic for anti-seizure, anti-inflammatory, anti-shock, anti-thrombus, hypotensive, analgesia, anti-psychotic, Parkinson's disease, gastrointestinal disorders, depressive states, cognitive dysfunction, anxiety, tardive dyskinesia, drug dependency, panic attack, mania, irritable bowel syndrome, diarrhea, ulcer, GI tumors, Tourette's syndrome, Huntington's chorea, vascular leakage, anti-arteriosclerosis, vascular and vasodilation disorders, as well as neurological, neuropharmalogical and neuropsychopharmacological disorders.Type: ApplicationFiled: October 29, 2003Publication date: April 15, 2004Applicant: Cognetix, Inc.Inventors: John D. Wagstaff, Richard T. Layer, R. Tyler McCabe
-
Patent number: 6696408Abstract: The present invention is directed to contulakin-G (which is the native glycosylated peptide), a des-glycosylated contulakin-G (termed Thr10-contulakin-G), and derivatives thereof, to a cDNA clone encoding a precursor of this mature peptide and to a precursor peptide. The invention is further directed to the use of this peptide as a therapeutic for anti-seizure, anti-inflammatory, anti-shock, anti-thrombus, hypotensive, analgesia, anti-psychotic, Parkinson's disease, gastrointestinal disorders, depressive states, cognitive dysfunction, anxiety, tardive dyskinesia, drug dependency, panic attack, mania, irritable bowel syndrome, diarrhea, ulcer, GI tumors, Tourette's syndrome, Huntington's chorea, vascular leakage, anti-arteriosclerosis, vascular and vasodilation disorders, as well as neurological, neuropharmalogical and neuropsychopharmacological disorders.Type: GrantFiled: June 29, 2000Date of Patent: February 24, 2004Assignees: University of Utah Research Foundation, Cognetix, Inc.Inventors: A. Grey Craig, David Griffen, Baldomero M. Olivera, Maren Watkins, David R. Hillyard, Julita Imperial, Lourdes J. Cruz, John D. Wagstaff, Richard T. Layer, Robert M. Jones, R. Tyler McCabe
-
Publication number: 20030181368Abstract: The present invention is directed to kappaA (&kgr;A) conopeptides and the use of these peptides for blocking the flow of potassium ions through voltage-gated potassium channels. The &kgr;A conopeptides include unglycosylated and O-glycosylated peptides.Type: ApplicationFiled: May 7, 2002Publication date: September 25, 2003Inventors: Richard T. Layer, Karen E. Pemberton, Robert M. Jones, James L. Garrett, Baldomero M. Olivera, J. Michael McIntosh, David R. Hillyard, Michelle Grilley, Maren Watkins, Ameurfina D. Santos, Glenn Zafaralla, A. Grey Craig
-
Publication number: 20030050435Abstract: The invention relates to relatively short peptides (termed &agr;-conotoxins herein), about 10-25 residues in length, which are naturally available in minute amounts in the venom of the cone snails or analogous to the naturally available peptides, and which preferably include two disulfide bonds. The &agr;-conotoxins, as described herein, are useful for as neuromuscular blocking agents, such as muscle relaxants.Type: ApplicationFiled: July 20, 2001Publication date: March 13, 2003Applicant: UNIVERSITY OF UTAH RESEARCH FOUNDATIONInventors: Baldomero M. Olivera, Richard T. Layer, Maren Watkins, David R. Hillyard, J. Michael McIntosh, Robert Schoenfeld, Jacob Scott Nielsen, Robert M. Jones
-
Patent number: 6515103Abstract: The present invention is directed to conantokin peptides, conantokin peptide derivatives and conantokin peptide chimeras, referred to collectively as conantokins, having 10-30 amino acids, including preferably two or more &ggr;-carboxyglutamic acid residues. The conantokins are useful for the treatment of neurologic and psychiatric disorders, such as anticonvulsant agents, neuroprotective agents or analgesic agents.Type: GrantFiled: May 11, 2000Date of Patent: February 4, 2003Assignees: University of Utah Research Foundation, Cognetix, Inc., Salk InstituteInventors: Fe C. Abogadie, Lourdes J. Cruz, Baldomero M. Olivera, Craig Walker, Clark Colledge, David R. Hillyard, Elsie Jimenez, Richard T. Layer, Li-Ming Zhou, Gregory S. Shen, R. Tyler McCabe, Jean E. Rivier
-
Publication number: 20020198145Abstract: The present invention is directed to the new &mgr;O-conopeptides, their coding sequences and their propeptides and to the use of &mgr;O-conopeptides as a local anesthetic for treating pain. The &mgr;O-conopeptides have long lasting anesthetic activity and are particularly useful for spinal anesthesia, either administered acutely for post-operative pain or via an intrathecal pump for severe chronic pain situations or for treatment of pain in epithelial tissue.Type: ApplicationFiled: July 20, 2001Publication date: December 26, 2002Applicant: COGNETIX, INC.Inventors: Baldomero M. Olivera, J. Michael McIntosh, R. Tyler McCabe, James E. Garrett, Richard T. Layer, John D. Wagstaff, Robert M. Jones
-
Patent number: 6489298Abstract: The present invention is directed to contulakin-G (which is the native glycosylated peptide), a des-glycosylated contulakin-G (termed Thr10-contulakin-G), and derivatives thereof, to a cDNA clone encoding a precursor of this mature peptide and to a precursor peptide. The invention is further directed to the use of this peptide as a therapeutic for anti-seizure, anti-inflammatory, anti-shock, anti-thrombus, hypotensive, analgesia, anti-psychotic, Parkinson's disease, gastrointestinal disorders, depressive states, cognitive dysfunction, anxiety, tardive dyskinesia, drug dependency, panic attack, mania, irritable bowel syndrome, diarrhea, ulcer, GI tumors, Tourette's syndrome, Huntington's chorea, vascular leakage, anti-arteriosclerosis, vascular and vasodilation disorders, as well as neurological, neuropharmalogical and neuropsychopharmacological disorders.Type: GrantFiled: June 29, 2000Date of Patent: December 3, 2002Assignee: Cognetix, Inc.Inventors: A. Grey Craig, David Griffen, Baldomero M. Olivera, Maren Watkins, David R. Hillyard, Julita Imperial, Lourdes J. Cruz, John D. Wagstaff, Richard T. Layer, Robert M. Jones, R. Tyler McCabe
-
Publication number: 20020173449Abstract: The invention relates to relatively short peptides (termed O-Superfamily conotoxins herein), about 20-40 residues in length, which are naturally available in minute amounts in the venom of the cone snails or analogous to the naturally available peptides, and which preferably include two disulfide bonds.Type: ApplicationFiled: December 28, 2000Publication date: November 21, 2002Inventors: Baldomero M. Olivera, G. Edward Cartier, Maren Watkins, David R. Hillyard, J. Michael McIntosh, Richard T. Layer, Robert M. Jones
-
Patent number: 6399574Abstract: The present invention is directed to the use of conantokin peptides, conantokin peptide derivatives and conantokin peptide chimeras, referred to collectively as conantokins, having 10-30 amino acids, including preferably two or more &ggr;-carboxyglutamic acid residues, for the treatment of neurologic and psychiatric disorders, such as anticonvulsant agents, neuroprotective agents or analgesic agents.Type: GrantFiled: March 22, 2000Date of Patent: June 4, 2002Assignees: University of Utah Research Foundation, Cognetix, Inc.Inventors: R. Tyler McCabe, Li-Ming Zhou, Richard T. Layer, Baldomero M. Olivera, J. Michael McIntosh
-
Patent number: 6344551Abstract: The present invention is directed to contulakin-G (which is the native glycosylated peptide), a des-glycosylated contulakin-G (termed Thr10-contulakin-G), and derivatives thereof, to a cDNA clone encoding a precursor of this mature peptide and to a precursor peptide. The invention is further directed to the use of this peptide as a therapeutic for anti-seizure, anti-inflammatory, anti-shock, anti-thrombus, hypotensive, analgesia, anti-psychotic, Parkinson's disease, gastrointestinal disorders, depressive states, cognitive dysfunction, anxiety, tardive dyskinesia, drug dependency, panic attack, mania, irritable bowel syndrome, diarrhea, ulcer, GI tumors, Tourette's syndrome, Huntington's chorea, vascular leakage, anti-arteriosclerosis, vascular and vasodilation disorders, as well as neurological, neuropharmalogical and neuropsychopharmacological disorders.Type: GrantFiled: June 29, 2000Date of Patent: February 5, 2002Assignee: University of Utah Research FoundationInventors: A. Grey Craig, David Griffin, Baldomero M. Olivera, Maren Watkins, David R. Hillyard, Julita Imperial, Lourdes J. Cruz, John D. Wagstaff, Richard T. Layer, Robert M. Jones, R. Tyler McCabe
-
Patent number: 6277825Abstract: The present invention is directed to the use of conantokin peptides, conantokin peptide derivatives and conantokin peptide chimeras, referred to collectively as conantokins, having 10-30 amino acids, including preferably two or more &ggr;-carboxyglutamic acid residues, for the treatment of neurologic and psychiatric disorders, such as pain, e.g., as an analgesic agent.Type: GrantFiled: July 20, 1999Date of Patent: August 21, 2001Assignees: University of Utah Research Foundation, Cognetix, Inc.Inventors: Baldomero M. Olivera, J. Michael McIntosh, R. Tyler McCabe, Richard T. Layer, Li-Ming Zhou
-
Patent number: 6268473Abstract: The invention relates to relatively short peptides (termed &agr;-conotoxins herein), about 10-25 residues in length, which are naturally available in minute amounts in the venom of the cone snails or analogous to the naturally available peptides, and which preferably include two disulfide bonds. The &agr;-conotoxins, as described herein, are useful for as neuromuscular blocking agents, such as muscle relaxants.Type: GrantFiled: January 21, 2000Date of Patent: July 31, 2001Assignees: University of Utah Research Foundation, Cognetix, Inc.Inventors: Baldomero M. Olivera, Richard T. Layer, Maren Watkins, David R. Hillyard, J. Michael McIntosh, Robert Schoenfeld, Robert M. Jones
-
Patent number: 6172041Abstract: The present invention is directed to the use of conantokin peptides, conantokin peptide derivatives and conantokin peptide chimeras, referred to collectively as conantokins, having 10-30 amino acids, including preferably two or more &ggr;-carboxyglutamic acid residues, for the treatment of neurologic and psychiatric disorders, such as anticonvulsant agents, neuroprotective agents or analgesic agents.Type: GrantFiled: February 10, 1999Date of Patent: January 9, 2001Assignees: University of Utah Research Foundation, Cognetix, Inc.Inventors: R. Tyler McCabe, Li-Ming Zhou, Richard T. Layer, Baldomero M. Olivera, J. Michael McIntosh